Loading...
NPI 1871988253 · Indianapolis, IN · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Aria Diagnostics LLC is a clinical medical laboratory provider located in Indianapolis, Indiana. This profile covers 7 Medicare and 61 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Aria Diagnostics LLC |
| Address | 5635 W 96th St |
| City | Indianapolis |
| State | IN |
| ZIP | 46278 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | April 1, 2015 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $3.9M |
| Medicare | $647.7K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
7 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4,050 | $110 | $453.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 2,410 | $60 | $147.2K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 120 | $240 | $30K |
| 88356 | After a lab analyst prepares slides, the qualified provider, typically a pathologist, performs a morphometric analysis to evaluate size, shape, and other physical features of a nerve. | 50 | $170 | $9.2K |
| 88342 | The lab analyst applies an initial single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 60 | $70 | $4.1K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 60 | $50 | $2.9K |
| 88314 | The lab analyst performs the technical lab steps to perform a histochemical stain on a frozen tissue block; this code also includes interpretation and a report. You should report this code separately… | 40 | $70 | $2.8K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 7 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
61 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 51,320 | $30 | $1.7M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 42,930 | $20 | $729.8K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 29,460 | $20 | $707.1K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 15,700 | $10 | $219.9K |
| 80355 | The lab analyst measures the amount of or detects the presence of gabapentin in the patient specimen, which is something other than blood. | 3,490 | $20 | $55.9K |
| 80323 | The lab analyst identifies and evaluates the level of alkaloid drugs in a patient specimen that are not specified elsewhere in CPT® by a different code from the class of alkaloids. | 1,560 | $30 | $52.9K |
| 80366 | The lab analyst measures the amount of or detects the presence of pregabalin, a drug that treats nerve pain and seizures, in a patient specimen. | 3,490 | $20 | $52.4K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 4,290 | $10 | $51.4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 630 | $70 | $41.8K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 5,070 | $10 | $25.4K |
Showing 1–10 of 61
How this provider's Medicaid billing volume and revenue compare to other Indiana providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Indiana median
61 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 20 | 1,610 | $70 | $841.6K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 12 | 30 | 400 | $90 | $443.4K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 9 | 190 | 800 | $40 | $344.7K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 58 | 90 | 1,150 | $60 | $289.6K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3 | 20 | 1,160 | $50 | $236.5K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 6 | 40 | 160 | $80 | $173.2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4 | 90 | 390 | $40 | $171.1K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 5 | 30 | 670 | $60 | $130.6K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 64 | 110 | 490 | $30 | $88.4K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 52 | 110 | 520 | $20 | $87.5K |
Showing 1–10 of 61
Other providers in the same ZIP code as Aria Diagnostics LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Patients Choice Laboratories Of Indiana, LLC | IN | Clinical Medical Laboratory | $17.3M | $23.4M |
| American Health Network Of Indiana, LLC | IN | Internal Medicine Physician | $0 | $15.3M |
| Kci Usa Inc. | IN | Durable Medical Equipment & Medical Supplies | $0 | $10.1M |
| Landmark Recovery Of Carmel LLC | IN | Substance Abuse Rehabilitation Facility | $0 | $6.4M |
| Pharmaneek Inc | IN | Pharmacy | $6.2M | $17.8K |
| Kacy Rogers | IN | Nurse Practitioner | $643.1K | $0 |
| Brian Wiegel | IN | Diagnostic Radiology Physician | $446.5K | $0 |
| Timothy Davis | IN | Diagnostic Radiology Physician | $429.5K | $0 |
| Florentino Ferrer | IN | Physical Therapist | $244.3K | $0 |
| Michael Conley | IN | Diagnostic Radiology Physician | $231.2K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.